drugset / Trial / NCT01196936
Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors
Phase 2
Active not recruiting
84 enrolled
University of Alabama at Birmingham
City of Hope National Medical Center · collabDana-Farber Cancer Institute · collabM.D. Anderson Cancer Center · collabMayo Clinic · collabNational Cancer Institute (NCI) · collabSt. Jude Children's Research Hospital · collabUniversity Health Network, Toronto · collabUniversity of Chicago · collabUniversity of Colorado, Denver · collabUniversity of Michigan · collabUniversity of Minnesota · collabUniversity of Washington · collabWake Forest University · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate may fight breast cancer by blocking the use of estrogen by the tumor cells This phase IIb trial studies how well low-dose tamoxifen citrate works in reducing breast cancer risk in radiation-induced cancer survivors.
Timeline
- Start
- 2010-09
- Primary completion
- 2018-12-11
- Completion
- 2028-12-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tamoxifen | Small molecule | 5 mg | Oral |